Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biotage and Peptide Synthesis

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
CEM claim to won a “patent dispute” with Biotage.

CEM Corporation has recently published a press release claiming to have won a “patent dispute” with Biotage. The so called “patent dispute” relates to Biotage’s filing of opposition against certain patents of CEM in Europe (Germany, France, Italy and Great Britain) and Japan, because Biotage believes that the patents as originally granted give CEM a broader protection than CEM is entitled to.

In April 2013 the Japanese Patent Office found that CEM’s patent, relating to microwave assisted solid phase peptide synthesis, is invalid.

Also the European Patent Office found that the scope of the corresponding European patent should be restricted.

The decisions by both patent offices were taken in response to the requests filed by Biotage. The decisions are open to appeal by both parties.

Biotage’s instruments for microwave assisted organic chemistry have been used in the scientific community since the late 1990s. Scientists took advantage of these early Biotage instruments to carry out microwave-assisted peptide synthesis more than ten years ago, even before CEM filed their first patent application in this field.

As early as in 2002, Professor Gogoll and his team at Uppsala University published an article entitled “Rapid Microwave-Assisted Solid Phase Peptide Synthesis” using a Biotage instrument.

This is part of Biotage’s heritage in the peptide synthesis business, which led the company to put more dedicated efforts into the peptide synthesis area, culminating in the launch of the Biotage® Syro Wave™ in 2010.

In 2012 Biotage launched the successful Biotage® Initiator+ Alstra™, which is the company’s latest automated microwave peptide synthesizer.

“Biotage of course respects third party patent rights. I am surprised that CEM claims that we are in a dispute and even more that they claim to have won. This is an ongoing discussion on what the fair scope of these patents is, if any. The CEM patents concerned do not cover Biotage’s line of instruments for microwave assisted peptide synthesis. All synthesis protocols preinstalled in the Biotage instruments are outside the patents, even as originally granted. The situation is the same with the corresponding US patents. This means that customers all over the world can continue to use Biotage’s microwave peptide synthesizers with the preinstalled methods. Peptide synthesis is a product area where Biotage will continue to grow and deliver exciting products to the market.” says Torben Jörgensen, CEO of Biotage.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Methods for the Extraction of Key Compounds for Clinical, Environmental and Forensic Applications
A new series of application notes utilizing the industry-standard RapidTrace® SPE Workstation for medicinal and analytical chemistry have been released.
Monday, January 10, 2011
Peptide Synthesis Webinar Series Introduces Second Installment: Synthesis of Difficult Peptide Sequences
Biotage announces the second installment in its series of webinars focusing on peptide synthesis.
Friday, October 29, 2010
Peptide Synthesis Webinar Series Introduces Second Installment: Synthesis of Difficult Peptide Sequences
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced the second installment in its series of webinars focusing on peptide synthesis.
Wednesday, October 27, 2010
Biotage Announces Research Collaboration with University of Copenhagen for Peptide Synthesis
Collaborations aims to develop new applications on the Biotage Syro Wave in the field of synthetic peptide and protein chemistry.
Thursday, May 13, 2010
Biotage Awarded Patent for Flash Purification Method Development and Optimization
The Company has been awarded U.S. patent 7686959: Control system and Method for Flash Separation.
Wednesday, April 21, 2010
Biotage Introduces EVOLUTE WCX: Now Providing a Total Solution for Basic Compounds
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the further expansion of its successful family of products with the launch of Evolute WCX.
Wednesday, March 17, 2010
Biotage Joins Forces with MultiSynTech and Enters the Peptide Synthesis Business
Biotage enters agreements concerning both the distribution rights for MultiSynTechs systems and the establishment of a joint development project.
Tuesday, February 24, 2009
Biotage Makes a Change in Top Management after Business Area President Resigns
David Patteson, President of the business area Discovery Chemistry will leave the company on 1 April 2006.
Tuesday, February 28, 2006
Biotage Receives its Largest Order to Date
Instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
Friday, August 12, 2005
Biotage expands European presence

Wednesday, April 09, 2003
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!